* Revenue $5.6 million vs. $8.4 million (In U.S. dollars unless noted)
TORONTO, Aug 12 (Reuters) - Drugmaker Aeterna Zentaris Inc AEZ.TO posted a smaller quarterly loss on Thursday, attributed to lower research and development costs and higher foreign exchange gains.
Aeterna, known for its cancer drugs, reported a second- quarter loss of $4.5 million, or 6 cents a share, compared with a loss of $13.1 million, or 24 cents a share, for the same period a year ago.
Analysts had expected a loss of 10 cents a share, according to Thomson Reuters I/B/E/S.
Revenue fell to $5.6 million for the period that ended June 30, from $8.4 million last year.
The Quebec City-based company has about $45.3 million cash and cash equivalents on hand. ($1=$1.05 Canadian) (Reporting by Solarina Ho, editing by Maureen Bavdek)